EmboCept® S is included in leading European guidelines for recommended therapeutic use
The Cardiovascular and Interventional Radiological Society of Europe (CIRSE) is dedicated to helping improve the quality of patient care in interventional radiology. In line with this, the society’s Standards of Practice Committee (SOPC) creates CIRSE Standards of Practice documents that assist interventional radiologists in their daily practice. The SOPC has confirmed the inclusion of degradable starch microspheres (DSM) for use in transarterial chemoembolization (DSM-TACE). Magle Chemoswed and PharmaCept hold originator status for this therapy using the proprietary starch microsphere technology platform of the company.
“This news confirms the effectiveness of DSM-TACE and strengthens the treatment options available to patients and physicians. As the owner of the underlying originator technology this is a great opportunity for us to further establish our market position and the market potential for our EmboCept®S product and for our new developments in the field” said Justin Pierce, CEO of Magle Chemoswed.
“This is a great success for the development of DSM, a great success for PharmaCept and a breakthrough for the treatment of patients with liver cancer”, added Dr. Jürgen Ebert, CEO of PharmaCept.
EmboCept® S is a vascular embolic agent made up of Magle Chemoswed’s proprietary DSM used to treat inoperable liver and lung tumours in conjunction with chemotherapies. EmboCept® S is used in transarterial chemoembolization or TACE that combines the local delivery of chemotherapy with a procedure called embolisation to treat cancer in the liver and lung. It is a non-surgical and minimally invasive procedure performed in radiology, usually by an interventional radiologist.
PharmaCept is a wholly owned subsidiary of Magle Chemoswed Holding and is focused on the development and direct sale of the Magle Chemoswed Holding group products to the market.